SecBot SecBot
8-K ·Filed May 19, 2026

INM

InMed Pharmaceuticals Inc.
BULLISH
Impact 8/10
Horizonmonths Processed6mo ago SEC0001213900-26-058795
8-K material event: Items 1.01, 5.01
Actionable Insight ▲ Bullish

The reverse merger and large PIPE validate Mentari's pipeline and provide ample capital. Monitor shareholder vote (INM requires 2/3 approval) and Nasdaq listing approval. The stock price may reflect the upcoming change in value but carries execution risk until closing.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.60
T+0 close · May 19, 2026 · via day close
Latest settled
−10.63%
T+60 · $1.43
Vs SPY
−16.92%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 19 $1.60entry
  2. T+1 · 6mo ago +0.63%α −0.41% · $1.61
  3. T+5 · 6mo ago +5.63%α +3.38% · $1.69
  4. T+20 · 5mo ago −6.88%α −7.86% · $1.49
  5. T+60 · 3mo ago −10.63%α −16.92% · $1.43
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InMed Pharmaceuticals (INM) entered into a definitive agreement to acquire Mentari Therapeutics via reverse merger, with Mentari shareholders receiving a majority stake in the combined entity. A concurrent PIPE of at least $150 million will fund operations and support the merged company's pipeline. The transaction includes a contingent value right for pre-merger INM shareholders and represents a transformative change of control.

Key Financial Metrics

Deal Type
merger

Key Facts

  • Reverse merger: INM acquires Mentari Therapeutics through merger subsidiaries; Mentari shareholders become majority owners of combined entity.
  • Mentari valued at $125 million (base Company Equity Value), subject to upward adjustment from PIPE proceeds.
  • Concurrent PIPE of at least $150 million from institutional investors, committed via securities purchase agreement.
  • Pre-merger INM shareholders receive one CVR per share, entitling them to future contingent payments.
  • Combined company to be renamed Mentari Therapeutics, Inc. and will continue trading on Nasdaq.
  • New directors and officers from Mentari will take control at closing.

Financial Impact

Mentari base valuation $125M; PIPE adds ≥$150M; combined entity post-money valuation substantially higher than INM's current ~$2M market cap.

dilutionmarket_capvaluation

Risk Factors

  • Failure to obtain required shareholder approval (two-thirds of INM shares).
  • Nasdaq listing not granted for combined company.
  • PIPE investors may not fund if conditions are not met; termination fee of $4M payable by Mentari if PIPE fails.
  • Delays beyond December 31, 2026 end date could terminate deal.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-058795
Document: ea029148201ex10-5.htm0001213900-26-058795
Document: ea029148201ex10-4.htm0001213900-26-058795

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 19, 2026